CASI Starts China Arm of Phase II Breast Cancer Trial

CASI Pharma, a US biopharma with strong China connections, has begun a China Phase II trial of its lead molecule, ENMD-2076, in triple-negative breast cancer. The trial is a China arm of an on-going Phase II test in the US. The China trial, which is being conducted at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing, will assess the safety and efficacy of ENMD-2076 in a Chinese population along with analysis of a bio-marker. More details.... Stock Symbol: (NSDQ: CASI) Share this with colleagues: // //